Form 4: RA Capital Director Receives Equity Grant in Acumen Pharma

Acumen Pharmaceuticals director Laura Stoppel received a grant of restricted stock units and stock options as part of her board compensation.

Summary

• Director Laura Stoppel was granted 35,500 restricted stock units (RSUs) on June 3, 2026.
• Director Laura Stoppel was granted an option to purchase 53,250 shares of common stock at an exercise price of $2.29 per share.
• Both the RSUs and the stock options are scheduled to vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting.
• The equity awards are held for the benefit of RA Capital Management funds, with proceeds intended to offset advisory fees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial trajectory.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule tied to service, promoting director retention.

Negatives

• Issuance of equity awards results in minor dilution to existing shareholders.

Risks

• Vesting is contingent upon Dr. Stoppel's continuous service to the issuer.
• Market price volatility could impact the future value of the granted options.

Future Outlook

The equity awards are expected to vest in full by the 2027 annual stockholder meeting, provided the director remains in service.

Management Comments

• The reporting persons disclaim beneficial ownership of the RSUs, the option, and the underlying common stock, noting they are held for the benefit of the RA Capital funds.

Industry Context

StockSavvy.ai notes that this filing reflects standard corporate governance practices for biotechnology companies, where board members are compensated with equity to ensure alignment with institutional investors.

Comparison to Industry Standards

• The use of RSU and option grants for board members is consistent with compensation practices for mid-cap and small-cap pharmaceutical companies.
• Vesting periods of one year are standard for non-employee director equity awards in the life sciences sector.

Corporate Governance

Related Party Transactions

• Dr. Stoppel holds the equity awards for the benefit of RA Capital funds, with proceeds used to offset advisory fees.

Stakeholder Impact

• Minor dilution for shareholders due to the issuance of new equity awards.

Next Steps

• Vesting of RSUs and options on the earlier of June 3, 2027, or the 2027 annual stockholder meeting.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, RA Capital Management, Director Compensation, Equity Grant, Insider Ownership